Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHA2 | P29317 | 2/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 5/20 | 0.42 |
| ▸ | RORC | P51449 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | HPGDS | O60760 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3331679 | 0.83 | GPR119 (0.48) | USP30SMN1; SMN2USP2GPR119HPGDS | |
| SCHEMBL3186642 | 0.83 | GPR119 (0.48) | USP30SMN1; SMN2USP2GPR119HPGDS | |
| SCHEMBL390649 | 0.81 | USP30 (0.48) | USP30GPR119RECQL | |
| SCHEMBL14280850 | 0.81 | USP30 (0.43) | USP30RORCSMN1; SMN2GPR119MEN1 | |
| SCHEMBL17224067 | 0.81 | EPHA2 (0.44) | EPHA2USP30RORCSMN1; SMN2USP2 | |
| SCHEMBL17236554 | 0.81 | EPHA2 (0.44) | EPHA2USP30RORCSMN1; SMN2USP2 | |
| SCHEMBL387472 | 0.79 | KDM4E (0.42) | SMN1; SMN2TSHR | |
| SCHEMBL17224078 | 0.78 | USP2 (0.43) | EPHA2USP30SMN1; SMN2USP2GPR119 | |
| SCHEMBL28659302 | 0.77 | EPHA2 (0.44) | EPHA2USP30RORCSMN1; SMN2USP2 | |
| SCHEMBL31223095 | 0.77 | PDE4B (0.47) | EPHA2USP30RORCGPR119RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101764-B2 | MCH receptor antagonists | ELI LILLY AND COMPANY (US) | 2012-01-24 | — | — | US | disclosed |
| US-20100016350-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2010-01-21 | — | — | US | disclosed |
| EP-2029610-A2 | NOVEL MCH RECEPTOR ANTAGONISTS | Eli Lilly & Company (US) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007146759-A2 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016350-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | MCHR1, MCHR2, MC1R | EPHA2 770/4885USP30 2497/4885RORC 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.